Brussels Metropolitan Area
Operating Partner | Venture Builder | Strategic Advisor I am a senior biopharmaceutical executive, biotech CEO and board member with 35+ years of global leadership experience across Roche, Novartis, Sanofi and UCB, spanning Europe, China and the US. Throughout my career, I have led global franchises, strategic partnerships, corporate transformations and transactions, managing multi-billion-dollar businesses and creating value across the entire biopharma lifecycle—from asset selection and development through commercialization and portfolio optimization. Today, through AXXELIS, I work alongside investors, biotech companies and leadership teams to translate exceptional science into global value creation. My focus is not traditional consulting. I operate at the intersection of: -Science and development -Capital and strategic partnerships -Venture creation -Cross-border execution I help management teams and investors navigate critical value inflection points by combining operating experience with access to a curated ecosystem of scientific, development and commercial capabilities. Areas of focus ▪ Asset strategy and value creation ▪ Investment-grade diligence and portfolio decisions ▪ Development acceleration from pre-IND to proof-of-concept ▪ Venture creation and NewCo formation ▪ Strategic partnering and transaction execution ▪ Europe–China–US innovation ecosystems Typical roles ▪ Operating Partner for life sciences investors, venture funds and family offices ▪ Strategic Advisor to biotech CEOs and leadership teams ▪ Board Advisor to private and venture-backed biotech companies ▪ Venture Partner supporting company creation and asset-centric investment opportunities ▪ Investment Committee Advisor providing clinical, commercial and strategic diligence ▪ Portfolio Company Advisor supporting transformation and value creation initiatives ▪ Interim Executive and Special Situations Partner for selected strategic assignments ▪ Cross-Border Partner for transactions, NewCo formation and global partnering initiatives Selected engagement models • Operating Partner • Venture Partner • Senior Advisor • Board Advisor • Investment Committee Advisor • Due Diligence Advisor • Portfolio Company Transformation Partner • Venture Creation Partner Operating Partner and Venture Builder helping exceptional science translate into global value creation.
I support the leadership team at YolTech with their overseas BD strategies. YolTech is a late clinical-stage, fully integrated in vivo gene-editing company developing one-time, potentially curative therapies. Its proprietary editing platform, validated LNP delivery, and in-house manufacturing have enabled six clinical programs, including a pivotal-stage PH1 asset and Phase 2/3-ready AATD program, with early human data supporting strong efficacy and safety. www.yoltx.com
AXXELIS is a curated group of senior operators integrating science, development, capital and strategic partnerships to maximize value creation around breakthrough life science innovations. We combine operating experience with a selective network of development, commercial and investment capabilities to support: • Asset strategy and investment-grade diligence • Development acceleration and NewCo formation • Portfolio company transformation • Strategic partnering • Europe–China–US transactions and ecosystem building Selected Ongoing Engagements: • YolTech Therapeutics (Shanghai, CN), late clinical-stage, fully integrated in vivo gene-editing biotech • Development of Next-Gen Biotech NewCo incubation model • EU–China biotech innovation bridge initiatives connecting science, capital, and commercialization
o Led China strategy and full P&L ownership (€141M revenue - 50% EBITDA) o Directed business transformation, capability upgrade, operational efficiency o Executed €600M carve-out and strategic partnership transactions o Restructured China footprint (465 employees, commercial +manufacturing) o Implemented launch readiness for rare disease and immunology assets o Shaped global CNS strategy leading to biotech acquisitions (Engage Therapeutics, Zogenix) o Drove portfolio prioritization and capital allocation decisions at executive level
Biotech specialized in Innovative medical devices and bio-artificial pancreas technology
UCB Ventures backed - Start-up company specialized in innovative digital solutions.